Printer Friendly

TrovaGene, Inc. Announces Name and Ticker Symbol Change.

SAN DIEGO -- TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK) a developer of transrenal molecular diagnostics, announced today that it has changed its name from Xenomics, Inc. to TrovaGene, Inc. and re-domesticated its state of incorporation to Delaware from Florida. The Company's stock symbol has been changed to TROV effective March 1, 2010.

"TrovaGene's programs are targeted at high growth markets where we can capitalize on the strengths of our proprietary transrenal molecular diagnostic technology. This revolutionary technology allows rapid and comprehensive diagnosis of disease and will provide physicians with diagnostic information which enables personalized medical care for their patients." stated Bruce A. Huebner, CEO of TrovaGene. The Company has leased a 5000 sq. ft. facility in the Sorrento Valley area of San Diego and is in the process of completing all the necessary laboratory validations. TrovaGene expects to continue to expand its scientific team towards becoming a fully integrated diagnostic business by the end of the 2nd quarter of 2010. Products in various stages of commercialization include a molecular diagnostics test for mutations in the k-RAS gene in patients with solid tumor cancers and a novel HPV assay that detects the HPV genotypes related to cervical cancer.

About TrovaGene, Inc. (TROV.PK)

With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection and analysis, can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients.

TrovaGene has been issued three U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a European patent for the company's prenatal testing applications, as well as numerous pending patent applications.

Statements about TrovaGene's expectations, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, and dependence on key personnel, obtaining financing and other factors.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U9CA
Date:Mar 2, 2010
Words:444
Previous Article:Travelocity Business Teams up with Certify to Simplify Expense Management.
Next Article:Amtech Announces $8.5 Million in New Solar Orders.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters